ResMed vs Labcorp

Side-by-side comparison of AI visibility scores, market position, and capabilities

AI visibility is closely matched (76 vs 79)
ResMed logo

ResMed

LeaderHealthcare Tech

Sleep & Respiratory Devices

ResMed (RMD) reported ~$4.7B revenue in FY2024. Global leader in cloud-connected devices for sleep apnea, COPD, and out-of-hospital care, with 10M+ connected devices. HQ: San Diego.

AI VisibilityBeta
Overall Score
B76
Category Rank
#71 of 596
AI Consensus
83%
Trend
stable
Per Platform
ChatGPT
72
Perplexity
75
Gemini
71

About

ResMed Inc. is the global leader in cloud-connected medical devices and software for diagnosing and treating sleep apnea, chronic obstructive pulmonary disease (COPD), and other respiratory conditions in out-of-hospital settings. Founded in Sydney, Australia in 1989, the company designs and manufactures CPAP (continuous positive airway pressure) machines, masks, ventilators, and related accessories used by patients with obstructive sleep apnea — a condition affecting approximately 1 billion people globally that is chronically under-diagnosed and under-treated.

Full profile
Labcorp logo

Labcorp

LeaderHealthcare Tech

Enterprise

Burlington NC clinical laboratory services (NYSE: LH) ~$13.1B FY2024 revenue; Fortrea CRO spun off 2023, 2000+ PSC network, specialty oncology molecular testing competing with Quest Diagnostics.

AI VisibilityBeta
Overall Score
B79
Category Rank
#31 of 596
AI Consensus
68%
Trend
up
Per Platform
ChatGPT
74
Perplexity
82
Gemini
73

About

Laboratory Corporation of America Holdings (Labcorp) is a Burlington, North Carolina-based clinical laboratory and life sciences company — publicly traded on the New York Stock Exchange (NYSE: LH) as an S&P 500 Health Care component — providing diagnostic laboratory testing services for physicians, hospitals, health systems, and patients across the United States and internationally, and providing drug development laboratory services (biopharmaceutical clinical trial laboratory support) through approximately 60,000 employees. In fiscal year 2024, Labcorp reported revenues of approximately $13.1 billion from the Diagnostics segment — following the June 2023 separation of its Drug Development segment as Fortrea Holdings (NASDAQ: FTRE), an independent public company providing CRO (contract research organization) services to pharmaceutical and biotech clients. CEO Adam Schechter has focused the post-Fortrea Labcorp on the pure-play diagnostics business: clinical testing across 6,000+ test menu items (routine blood work, specialty genetic testing, toxicology, and anatomic pathology) processed at Labcorp's 2,000+ patient service centers and sent to regional and specialty reference laboratories for results reporting to ordering physicians. The Labcorp consumer-direct testing initiative (at-home specimen collection kits for STI testing, COVID testing, and other direct-to-consumer tests ordered at labcorp.com without physician referral) expands beyond the traditional physician-ordered testing model to capture the growing consumer health testing market. Labcorp's specialty testing portfolio (oncology genomic profiling, rare disease genetic panels, prenatal cell-free DNA testing, advanced cardiac biomarker panels) generates higher revenue per requisition than routine chemistry and hematology panels — driving mix shift toward specialty and molecular testing revenue.

Full profile

AI Visibility Head-to-Head

76
Overall Score
79
#71
Category Rank
#31
83
AI Consensus
68
stable
Trend
up
72
ChatGPT
74
75
Perplexity
82
71
Gemini
73
77
Claude
85
77
Grok
75

Key Details

Category
Sleep & Respiratory Devices
Enterprise
Tier
Leader
Leader
Entity Type
company
company

Capabilities & Ecosystem

Capabilities

Only ResMed
Sleep & Respiratory Devices

Integrations

Only Labcorp
ResMed is classified as company. Labcorp is classified as company.

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.